LB-101 News - LARVOL Sigma

|||||||||| LB101 / Centessa, LB-101 / LogicBio Therap
LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47). (Available On Demand; 217) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1622;
Single agent LB101 immunotherapy delivered systemically in a difficult to treat syngeneic mouse model resulted in PD-L1 directed, local tumor-specific CD47 effector engagement leading to significant tumor regressions as compared to atezolizumab without overt toxicity. Future developments will focus on developing LB101 as a single agent therapeutic and exploring the potential of LockBody technology in improving the therapeutic index of other anti-cancer biological effectors through conditional activation within the TME.



	Diseases Companies Products Productz Mechanisms of Action Sites